TCK-276 is under clinical development by Teijin Pharma and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TCK-276’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TCK-276 overview

TCK-276 is under development for the treatment of rheumatoid arthritis. It is administered through oral route as tablet.

Teijin Pharma overview

Teijin Pharma, a subsidiary of Teijin Ltd, develops, manufactures and markets pharmaceutical and home healthcare products. The company provides a range of pharmaceutical products for the treatment of bone and joint diseases, respiratory diseases and cardiovascular and metabolic diseases. It carries out research and development activities, manufacturing technology innovations and systems and product liability assessment systems. Teijin Pharma’s pipeline products are intended for the treatment of tumor lysis syndrome, adenosine deaminase deficiency, optic neuritis, microscopic polyangiitis, neuroendocrine tumor, and lumbar disc herniation, type 2 diabetes and others. The company’s pharmaceutical products comprise inhaled corticosteroids for asthma, osteoporosis drugs and anti-hyperuricemia agent. Teijin Pharma’s home healthcare equipment includes oxygen concentrators, a sonic accelerated fracture healing system, and continuous positive airway pressure devices. The company operates in Europe, Asia and North America. Teijin Pharma is headquartered in Chiyoda, Tokyo, Japan.

For a complete picture of TCK-276’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.